BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report

摘要: The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, the newest approach colorectal cancers. In this case report, we share our experience about use inhibitor vemurafenib on a metastatic right adenocarcinoma patient. A 59-year-old male with only lung multiple presented to clinic. patient was evaluated and FOLFOX + bevacizumab initiated, then continued vemurafenib. remarkable response achieved in drug resistance occurred approximately sixth month. Even though benefited majorly from vemurafenib, he died 20th month diagnosis. expected overall survival patients 4.7 months. inhibitors provide new alternatives cancers, prolonged survival. combination MEK reported feasible overcome phase studies still progress. To conclude, alone or other drugs chance curing patients.